The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The role of ESAs agents in low-risk MDS
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, talks on the use of erythropoietin stimulating agents (ESAs) in low-risk myelodysplastic syndromes (MDS), commenting on the results of a real-world study that demonstrated that ESAs allowed patients to maintain a good quality of life (QoL). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
